HR Execs on the Move

Berg Pharma

www.bergpharma.com

 
Berg Pharma focuses research on understanding how alterations in metabolism relate to disease onset. The company has a deep pipeline of early-stage technologies in CNS diseases and metabolic diseases that complement its late-stage clinical trial activity in cancer and prevention of chemotoxicity. Armed with use of the Berg Interrogative Biology™ discovery platform that translates biological output into therapeutic candidates, Berg Pharma is well positioned for rapid commercialization of its intellectual capital.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.bergpharma.com
  • 500 Old Connecticut Path
    Framingham, MA USA 01701
  • Phone: 617.588.0083

Executives

Name Title Contact Details

Similar Companies

MDC Associates

Supporting IVD innovators with RA/QA/CRO, FDA/CE IVD Submission, Training, Go-to-Market support and more.

Health Solutions Network

Health Solutions Network is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Flora Growth

Leading The Future of Cannabis

Novartis

Novartis provides healthcare solutions that improve and extend people`s lives. We use science-based innovation to address some of society`s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. Our company is focused on industry-leading divisions with innovation power and global scale: pharmaceuticals, eye care and generic medicines Novartis is headquartered in Basel, Switzerland. Novartis Group companies employ approximately 120,000 associates and its products are available in more than 180 countries around the world.

Amolyt Pharma

Amolyt Pharma is building on its team`s established expertise in therapeutic peptides development to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases. Amolyt Pharma`s programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism. The collaborative Amolyt Pharma team is well-equipped for upcoming milestones and for the adoption of additional programs as made possible by its global network in the field of endocrinology and with support from a strong syndicate of international investors.